Why the study?
What are the pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam in patients with essential hypertension?
What are the pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam in patients with essential hypertension?
Intravenous fenoldopam has a rapid onset of action, short elimination half-life, and linear dose-response relationship, suggesting utility for parenteral treatment of hypertension.
Answers are grounded in this paper and cite their sources.
Fenoldopam infusion supports predictable BP titration via log-linear PK/PD; leaves open comparative efficacy versus standard agents in acute hypertension.
1 The pharmacokinetic properties of intravenous fenoldopam, a selective dopamine1-receptor agonist, were studied in 10 patients with essential hypertension. 2 Reduction in blood pressure was linearly related to the log fenoldopam plasma concentration (r = 0.69) and the log fenoldopam infusion rate (r = 0.71). 3 The mean elimination half-life (+/- s. e. mean) was 9.8 +/- 1.0 min. The total body clearance was 30.3 +/- 2.3 ml kg-1 min-1 and the volume of distribution was 582 +/- 62 ml kg-1. 4 The rapid onset of action, short elimination half-life, linear dose-response relationship, and ease of administration suggest that fenoldopam may have a role where parenteral treatment of hypertension is required.
No takes yet. Share an insight, caveat, or question.
Rr et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: